Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures

Award Number: R01AR080118
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/12/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures - Project Summary / Abstract Atypical femoral fractures (AFFs) are a rare but devastating side effect of long-term bisphosphonate (BP) treatment. Despite the relatively low prevalence of AFFs, public awareness has considerably depressed osteoporosis medication adherence. The mechanisms driving BP associated AFFs remain elusive and several mechanisms have been proposed, including impaired bone remodeling, altered bone matrix maturation, and the accumulation of tissue microdamage. A critical barrier to understanding how BPs negatively affect skeletal integrity is the difficulty in separating the individual contributions of altered remodeling kinetics (suppressed resorption and formation) from bone matrix maturation. We will overcome this barrier with our recently validated rat model of induced cortical remodeling to investigate mechanism and treatment, based on robust preliminary work in the laboratories of the three multiPIs. The current proposal, submitted in response to a notice of special interest on AFF pathophysiology (NOT-AR-21-006), will test the central hypothesis that BPs degrade skeletal integrity by affecting both the initiation of bone formation and matrix maturation. In Aims 1 and 2, we will focus on alendronate because of its strong association with the development of AFFs and raloxifene as a potential mitigating treatment due to its reported positive effects on both the formation and matrix maturation processes. Specifically, we will investigate the effects of alendronate and raloxifene on the initiation of bone formation, concentrating on the role of reversal cells (Aim 1) and the remodeling independent effects of these two drugs on matrix maturation and fatigue life (Aim 2). To determine if BP molecular structure could play a role in AFF susceptibility, we will also compare how alendronate, zoledronate, risedronate, and ibandronate affect bone formation, matrix maturation, and fatigue life (Aim 3). We will utilize an innovative preclinical model and leverage the expertise of a highly qualified research team to address critical questions associated with AFFs. If successful, the project will (i) further the understanding of the consequences of BP usage on the skeleton by disentangling bone formation initiation and matrix maturation, identifying factors that contribute to BP-induced loss of fatigue life and (ii) examine raloxifene as a novel rapid treatment option for patients at risk for BP-induced AFF.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $353,132 )
2025	2025	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	3/3/2025	NON-COMPETING CONTINUATION	$353,132
														Subtotal = $353,132

Issue Date FY: 2024 ( Subtotal = $391,487 )
2024	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	6/13/2024	NON-COMPETING CONTINUATION	$28,251
2024	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	3/18/2024	NON-COMPETING CONTINUATION	$363,236
														Subtotal = $391,487

Issue Date FY: 2023 ( Subtotal = $464,873 )
2023	2023	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	5/12/2023	NEW	$464,873
														Subtotal = $464,873

Grand Total All Awards = $1,209,492

Top

All Categories

About

Search

Reports

Data Submission

Award Information

How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures

Award Number: R01AR080118

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/12/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer